The U.S. Army is expected to announce that it has developed a vaccine that protects against omicron and other COVID-19 variants. The Walter Reed Army Institute of Research (WRAIR) has been developing a Spike Ferritin Nanoparticle (SpFN) since early 2020, and began early-stage human trials of the vaccine in early April. Kayvon Modjarrad, director of WRAIR’s infections disease branch, said that the early-stage trials ended this month, and yielded positive results that are currently under review.
-a slight correction, but still promising.
Correction: This headline and story have been corrected to reflect that the COVID-19 vaccine the Army is developing has not been tested against omicron.
The U.S. Army is expected to announce that it has developed a vaccine that protects against an array of COVID-19 variants, Defense One reported.
The Walter Reed Army Institute of Research (WRAIR) has been developing a spike ferritin nanoparticle (SpFN) vaccine since early 2020 and began early-stage human trials of the vaccine in early April.
Comments are closed.